Immuneering (IMRX) Stock Forecast, Price Target & Predictions
IMRX Stock Forecast
Immuneering stock forecast is as follows: an average price target of $17.50 (represents a 840.86% upside from IMRX’s last price of $1.86) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
IMRX Price Target
The average price target for Immuneering (IMRX) is $17.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $41.00 to $3.00. This represents a potential 840.86% upside from IMRX's last price of $1.86.
IMRX Analyst Ratings
According to 3 Wall Street analysts, Immuneering's rating consensus is 'Buy'. The analyst rating breakdown for IMRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immuneering Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 02, 2024 | Graig Suvannavejh | Mizuho Securities | $8.00 | $2.75 | 190.91% | 330.11% |
| Mar 15, 2024 | Michael Yee | Jefferies | $3.00 | $1.91 | 57.07% | 61.29% |
| Sep 30, 2022 | Swapnil Malekar | Piper Sandler | $41.00 | $15.50 | 164.52% | 2104.30% |
| Jul 09, 2022 | Geulah Livshits | Loop Capital Markets | $18.00 | $7.28 | 147.25% | 867.74% |
The latest Immuneering stock forecast, released on Apr 02, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $8.00, which represents a 190.91% increase from the stock price at the time of the forecast ($2.75), and a 330.11% increase from IMRX last price ($1.86).
Immuneering Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $5.50 |
| Last Closing Price | $1.86 | $1.86 | $1.86 |
| Upside/Downside | -100.00% | -100.00% | 195.70% |
In the current month, the average price target of Immuneering stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immuneering's last price of $1.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 19, 2023 | Mizuho Securities | - | Buy | Upgrade |
| Jul 25, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 09, 2022 | Chardan Capital | - | Buy | Initialise |
Immuneering's last stock rating was published by Mizuho Securities on Apr 19, 2023. The company Upgrade its IMRX rating from "null" to "Buy".
Immuneering Financial Forecast
Immuneering Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $456.00 | $38.38K | $94.42K | $183.70K | $2.08B | $482.13K | $660.04K |
| Avg Forecast | - | - | - | - | - | - | - | $8.33K | $60.00K | $153.33K | $196.80K | $182.00K | $535.50K | $700.00K | $725.00K |
| High Forecast | - | - | - | - | - | - | - | $8.33K | $60.00K | $153.33K | $196.80K | $182.00K | $535.50K | $700.00K | $725.00K |
| Low Forecast | - | - | - | - | - | - | - | $8.33K | $60.00K | $153.33K | $196.80K | $182.00K | $535.50K | $700.00K | $725.00K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 0.01% | 0.25% | 0.48% | 1.01% | 3880.62% | 0.69% | 0.91% |
Immuneering's average Quarter revenue forecast for Mar 23 based on 1 analysts is $8.33K, with a low forecast of $8.33K, and a high forecast of $8.33K. IMRX's average Quarter revenue forecast represents a 1727.41% increase compared to the company's last Quarter revenue of $456.00 (Dec 22).
Immuneering EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-14.49M | $-13.98M | $-12.98M | $-11.44M | $-12.73M | $-14.68M | $-8.50M | $-7.95M |
| Avg Forecast | - | - | - | - | - | - | - | $-5.00K | $-36.00K | $-92.00K | $-118.08K | $-11.45M | $-321.30K | $-10.45M | $-435.00K |
| High Forecast | - | - | - | - | - | - | - | $-5.00K | $-36.00K | $-92.00K | $-118.08K | $-9.16M | $-321.30K | $-8.36M | $-435.00K |
| Low Forecast | - | - | - | - | - | - | - | $-5.00K | $-36.00K | $-92.00K | $-118.08K | $-13.74M | $-321.30K | $-12.54M | $-435.00K |
| Surprise % | - | - | - | - | - | - | - | 2898.50% | 388.27% | 141.13% | 96.91% | 1.11% | 45.69% | 0.81% | 18.27% |
undefined analysts predict IMRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immuneering's previous annual EBITDA (undefined) of $NaN.
Immuneering Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $1.06B | $-12.51M | $-12.50M | $-11.41M | $-12.87M | $-14.37M | $-8.53M | $-7.99M |
| Avg Forecast | $-11.42M | $-10.38M | $-9.93M | $-10.82M | $-12.82M | $-16.36M | $-15.42M | $-16.05M | $-16.65M | $-14.23M | $-15.21M | $-11.75M | $-11.45M | $-10.49M | $-49.08M |
| High Forecast | $-11.42M | $-10.38M | $-9.93M | $-10.82M | $-12.82M | $-14.85M | $-15.42M | $-16.05M | $-16.65M | $-14.23M | $-15.21M | $-9.40M | $-11.45M | $-8.39M | $-49.08M |
| Low Forecast | $-11.42M | $-10.38M | $-9.93M | $-10.82M | $-12.82M | $-17.58M | $-15.42M | $-16.05M | $-16.65M | $-14.23M | $-15.21M | $-14.10M | $-11.45M | $-12.59M | $-49.08M |
| Surprise % | - | - | - | - | - | - | - | -66.16% | 0.75% | 0.88% | 0.75% | 1.10% | 1.26% | 0.81% | 0.16% |
Immuneering's average Quarter net income forecast for Jun 24 is $-15.42M, with a range of $-15.42M to $-15.42M. IMRX's average Quarter net income forecast represents a -101.45% decrease compared to the company's last Quarter net income of $1.06B (Mar 23).
Immuneering SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $4.46M | $4.11M | $3.84M | $3.70M | $3.95M | $3.79M | $2.60M | $1.34M |
| Avg Forecast | - | - | - | - | - | - | - | $94.95K | $683.67K | $1.75M | $2.24M | $2.07M | $6.10M | $7.98M | $8.26M |
| High Forecast | - | - | - | - | - | - | - | $94.95K | $683.67K | $1.75M | $2.24M | $2.07M | $6.10M | $7.98M | $8.26M |
| Low Forecast | - | - | - | - | - | - | - | $94.95K | $683.67K | $1.75M | $2.24M | $2.07M | $6.10M | $7.98M | $8.26M |
| Surprise % | - | - | - | - | - | - | - | 46.98% | 6.01% | 2.20% | 1.65% | 1.91% | 0.62% | 0.33% | 0.16% |
Immuneering's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to IMRX last annual SG&A of $4.46M (Mar 23).
Immuneering EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $40.16 | $-0.47 | $-0.47 | $-0.43 | $-0.49 | $-0.55 | $-0.47 | $-0.33 |
| Avg Forecast | $-0.39 | $-0.35 | $-0.34 | $-0.36 | $-0.43 | $-0.55 | $-0.52 | $-0.54 | $-0.56 | $-0.48 | $-0.51 | $-0.44 | $-0.39 | $-0.56 | $-1.66 |
| High Forecast | $-0.39 | $-0.35 | $-0.34 | $-0.36 | $-0.43 | $-0.50 | $-0.52 | $-0.54 | $-0.56 | $-0.48 | $-0.51 | $-0.44 | $-0.39 | $-0.56 | $-1.66 |
| Low Forecast | $-0.39 | $-0.35 | $-0.34 | $-0.36 | $-0.43 | $-0.59 | $-0.52 | $-0.54 | $-0.56 | $-0.48 | $-0.51 | $-0.44 | $-0.39 | $-0.56 | $-1.66 |
| Surprise % | - | - | - | - | - | - | - | -74.20% | 0.84% | 0.98% | 0.84% | 1.12% | 1.42% | 0.84% | 0.20% |
According to 0 Wall Street analysts, Immuneering's projected average Quarter EPS for Jun 24 is $-0.52, with a low estimate of $-0.52 and a high estimate of $-0.52. This represents a -101.29% decrease compared to IMRX previous annual EPS of $40.16 (Mar 23).
Immuneering Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| IVA | Inventiva | $2.76 | $36.00 | 1204.35% | Buy |
| IMRX | Immuneering | $1.86 | $17.50 | 840.86% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| GOSS | Gossamer Bio | $0.89 | $3.75 | 321.35% | Buy |
| CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| CELC | Celcuity | $15.36 | $31.50 | 105.08% | Buy |
| NAMS | NewAmsterdam Pharma Company | $18.03 | $36.50 | 102.44% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
| ELVN | Enliven Therapeutics | $27.65 | $35.50 | 28.39% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
IMRX Forecast FAQ
Is Immuneering a good buy?
Yes, according to 3 Wall Street analysts, Immuneering (IMRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of IMRX's total ratings.
What is IMRX's price target?
Immuneering (IMRX) average price target is $17.5 with a range of $3 to $41, implying a 840.86% from its last price of $1.86. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immuneering stock go up soon?
According to Wall Street analysts' prediction for IMRX stock, the company can go up by 840.86% (from the last price of $1.86 to the average price target of $17.5), up by 2104.30% based on the highest stock price target, and up by 61.29% based on the lowest stock price target.
Can Immuneering stock reach $3?
IMRX's average twelve months analyst stock price target of $17.5 supports the claim that Immuneering can reach $3 in the near future.
What are Immuneering's analysts' financial forecasts?
Immuneering's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-44.607M (high $-43.092M, low $-45.819M), average SG&A $0 (high $0, low $0), and average EPS is $-1.504 (high $-1.453, low $-1.545). IMRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.553M (high $-42.553M, low $-42.553M), average SG&A $0 (high $0, low $0), and average EPS is $-1.435 (high $-1.435, low $-1.435).
Did the IMRX's actual financial results beat the analysts' financial forecasts?
Based on Immuneering's last annual report (Dec 2022), the company's revenue was $316.95K, which missed the average analysts forecast of $592.13K by -46.47%. Apple's EBITDA was $-51.715M, beating the average prediction of $-11.693M by 342.29%. The company's net income was $-49.282M, missing the average estimation of $-57.84M by -14.80%. Apple's SG&A was $15.61M, beating the average forecast of $6.75M by 131.31%. Lastly, the company's EPS was $-1.87, missing the average prediction of $-1.993 by -6.15%. In terms of the last quarterly report (Dec 2022), Immuneering's revenue was $456, missing the average analysts' forecast of $60K by -99.24%. The company's EBITDA was $-13.978M, beating the average prediction of $-36K by 38726.92%. Immuneering's net income was $-12.506M, missing the average estimation of $-16.648M by -24.88%. The company's SG&A was $4.11M, beating the average forecast of $683.67K by 500.63%. Lastly, the company's EPS was $-0.47, missing the average prediction of $-0.561 by -16.29%